![]() |
市场调查报告书
商品编码
1519491
2024-2032 年按类型、技术、应用和地区分類的基因检测市场报告Genetic Testing Market Report by Type, Technology, Application, and Region 2024-2032 |
IMARC Group年全球基因检测市场规模达177亿美元。这个市场主要由技术进步、大众对个人化医疗的需求不断增长、遗传性疾病患病率增加、政府支持性倡议的出台以及伦理、法律和社会考虑的影响不断增加所推动。
市场成长与规模:随着公众的资讯更加丰富以及对个人化医疗的需求增加,该产业正在强劲成长。随着检测技术的进步,市场正在以极快的速度渗透到新的医疗保健领域,并已成为医疗保健行业中最具活力的领域之一。
主要市场驱动因素:主要因素是新技术的引入、遗传疾病和慢性病盛行率的增加以及消费者对遗传风险知识的增加。政府对基因研究的倡议和资助也极大地帮助了该行业的市场成长,这为基因检测市场有多大提供了准确的答案。
技术进步:NGS(下一代定序)和 CRISPR 技术的创新彻底改变了测试,提供了精确且经济实惠的方法。这些发展扩大了基因检测的范围和机会,从而增加了其在临床环境和研究中的使用。
产业应用:检测应用包括癌症诊断、遗传疾病诊断、心血管疾病诊断等。它可用于诊断和管理遗传疾病,使其成为现代医疗保健不可分割的一部分。
主要市场趋势:人们越来越喜欢直接面向消费者的服务,在这种服务中,使用者无需医生干预即可获取遗传资讯。市场也经历了一种趋势,即检测正在成为疾病筛检和管理的常规医疗保健实践的一部分,这表明基因检测市场的未来前景乐观。
地理趋势:北美占据市场主导地位,其次是欧洲和亚太地区。医疗设施、人均医疗支出和政府援助等因素也促进了这些地区的发展。儘管当前面临挑战,拉丁美洲、中东和非洲的新兴市场仍显示出成长潜力。
竞争格局:市场竞争激烈,主要参与者从事研发、策略伙伴关係和监管合规。这些公司专注于扩大其测试产品组合併探索新的市场机会以保持竞争优势。
挑战与机会:虽然市场提供了大量的成长机会,但它也面临着诸如测试的道德和法律影响、对熟练专业人员的需求以及公众认知问题等挑战。应对这些挑战并利用技术进步为市场扩张和创新提供了重大机会。
基因检测技术的进步
基因检测技术的进步有助于推动基因检测市场的规模。这些技术创新带来了更准确、更有效率、更具成本效益的基因分析方法,将检测范围扩大到肿瘤学、药物基因组学和预测检测等领域,进一步推动基因检测市场的成长。增强型定序技术,例如下一代定序(NGS),可以提供对遗传性疾病的详细了解,从而实现早期检测和个人化治疗计划。例如,
一项针对1914 名女性的研究表明,与标准筛检相比,cfDNA 检测显着降低了21 三体和18 三体的假阳性率,检测非整倍体的成功率为100%,预测值更高。此外,简化的流程增加了基因检测在各种医疗保健环境中的采用,从而促进了基因检测市场的需求。
对个人化医疗的认识和需求不断增加
对个人化医疗的认识和需求的不断提高也在塑造基因检测市场前景方面发挥了重要作用。个人化医疗依赖遗传资讯来客製化治疗,这增加了对基因测试的需求。这种需求在肿瘤学和生殖健康等领域尤其明显,在这些领域,基因检测指导治疗决策并评估后代的遗传性疾病风险。例如,根据一项研究,回覆率为 36% 的调查显示,312 名受访者中,83% 对直接面向消费者的基因检测询问最少,14% 涉及结果解释,超过 50% 的人支持遗传咨询师和临床环境进行基因检测,70% 的人愿意考虑对有隐私、匿名或访问问题的患者进行基因检测。此外,消费者对了解健康状况遗传倾向的兴趣日益浓厚,进一步推动了基因检测市场的概况,推动了基因检测市场统计数据和基因检测市场趋势。
遗传性疾病和慢性病的增加
全球遗传性疾病和慢性病的增加进一步加剧了基因检测市场的统计数据。基因检测在囊性纤维化、镰状细胞性贫血和亨廷顿舞蹈症等各种疾病的早期检测、诊断和治疗中发挥着至关重要的作用。此外,随着癌症、心血管疾病和糖尿病等慢性疾病发生率的不断增加,越来越需要透过检测来识别导致个体易患这些疾病的基因突变。世界卫生组织 (WHO) 报告称,癌症、心血管疾病和糖尿病等非传染性疾病 (NCD) 每年造成全球死亡人数的 73%。基因检测可以帮助识别有这些疾病风险的个体。透过测试进行早期发现可以改善患者的治疗结果,进一步推动基因检测市场的发展。基因检测市场规模庞大,美国等已开发国家每年基因检测数量大幅增加。展望未来,基因检测的未来充满希望,技术的持续进步有望提高准确性和可及性。妊娠基因检测也变得越来越普遍,为胎儿健康和遗传状况提供了宝贵的见解。
The global genetic testing market size reached US$ 17.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The market is primarily driven by technological advancements, rising demand for personalized medicine among the masses, increased prevalence of genetic disorders, introduction of supportive government initiatives, and rising implication of ethical, legal, and social considerations.
Market Growth and Size: The sector is seeing strong growth as the public becomes more informed and the appetite for personalized medicine increases. With advancements in testing technologies, the market is penetrating new healthcare sectors at an extremely rapid pace and has become one of the most dynamic segments of the healthcare industry.
Major Market Drivers: The main factors are the introduction of new technologies, the increase in the prevalence of genetic diseases and chronic conditions and the increasing of the consumer's knowledge about genetic risks. Government initiatives and funding of genetic research also greatly assist the industry in market growth, which provide an accurate answer to how big is the genetic testing market.
Technological Advancements: Innovations in NGS (next-generation sequencing) and CRISPR technologies have revolutionized testing providing precise and budget-friendly methods. These developments have enlarged the range and opportunity of genetic testing, which in turn has increased the usage of it both in clinical settings and in research.
Industry Applications: The application of the testing includes cancer diagnosis, genetic disease diagnosis, and cardiovascular disease diagnosis. It can be used for diagnosing and managing genetic diseases makes it an inseparable part of modern healthcare.
Key Market Trends: There is a rising preference for direct-to-consumer services, in which users can acquire genetic information without using an intervening doctor. The market is also experiencing a trend where testing is becoming part of regular healthcare practices for disease screening and management, which indicates a positive outlook for the future of genetic testing market.
Geographical Trends: North America dominates the market, followed by Europe and the Asia Pacific. Factors including healthcare facilities, per capita medical expenditure, and governmental assistance also contribute to the development of these regions. Emerging markets in Latin America and the Middle East and Africa show potential for growth despite current challenges.
Competitive Landscape: The market is highly competitive with key players engaging in research and development, strategic partnerships, and regulatory compliance. These companies are focusing on expanding their testing portfolios and exploring new market opportunities to maintain their competitive edge.
Challenges and Opportunities: While the market offers substantial growth opportunities, it faces challenges such as ethical and legal implications of testing, the need for skilled professionals, and public perception issues. Addressing these challenges and harnessing technological advancements present significant opportunities for market expansion and innovation.
Advancements in genetic testing technologies
Advancements in genetic testing technologies have been instrumental in driving the genetic testing market size. These technological innovations have led to more accurate, efficient, and cost-effective genetic analysis methods, expanding the scope of testing into areas such as oncology, pharmacogenomics, and predictive testing, further driving the genetic testing market growth. Enhanced sequencing techniques, such as next-generation sequencing (NGS), provide detailed insights into genetic disorders, enabling early detection and personalized treatment plans. For instance,
A study on 1914 women revealed cfDNA testing significantly reduces false positives for trisomies 21 and 18 compared to standard screening, with a 100% success rate in detecting aneuploidies and higher predictive values. Furthermore, simplified processes have increased the adoption of genetic testing across various healthcare settings, contributing to the genetic testing market demand.
Increasing awareness and demand for personalized medicine
Increasing awareness and demand for personalized medicine have also played a significant role in shaping the genetic testing market outlook. Personalized medicine, which relies on genetic information to tailor treatments, has heightened the demand for genetic tests. This demand is particularly evident in sectors such as oncology and reproductive health, where genetic testing guides therapy decisions and assesses genetic disorder risks in offspring. For example, according to a study, survey with a 36% response rate showed that 83% of the 312 respondents had minimal inquiries about direct-to-consumer genetic testing, 14% dealt with result interpretation, and over 50% supported the role of genetic counsellors and clinical settings for genetic testing, with 70% open to considering it for patients with privacy, anonymity, or access concerns. Additionally, growing consumer interest in understanding genetic predispositions to health conditions further fuels genetic testing market overview, driving genetic testing market statistics and genetic testing market trends.
Rise in genetic disorders and chronic diseases
The rise in genetic disorders and chronic diseases globally is further escalating the genetic testing market statistics. Genetic testing plays a vital role in the early detection, diagnosis, and management of various conditions such as cystic fibrosis, sickle cell anemia, and Huntington's disease. Moreover, with the increasing incidence of chronic diseases, including cancer, cardiovascular diseases, and diabetes, there is a heightened need for testing to identify genetic mutations predisposing individuals to these conditions. The World Health Organization (WHO) reports that non-communicable diseases (NCDs), such as cancer, cardiovascular diseases, and diabetes, are responsible for 73% of global deaths annually. Genetic testing can help identify individuals at risk for these conditions. Early detection through testing improves patient outcomes, further propels the genetic testing market. The genetic testing market is substantial, with a considerable growth in the number of genetic testing per year in USA and other developed countries. Looking ahead, the future of genetic testing is promising, with continued technological advancements expected to enhance accuracy and accessibility. Genetic testing in pregnancy is also becoming increasingly prevalent, providing valuable insights into fetal health and genetic conditions.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, technology, and application.
Predictive and Presymptomatic Testing
Carrier Testing
Prenatal and Newborn Testing
Diagnostic Testing
Pharmacogenomic Testing
Others
Diagnostic testing accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. According to the report, diagnostic testing represented the largest segment.
The largest sector of the market is the diagnostic testing market, which is employed to reveal or confirm specific inherited disease in symptomatic people. This sector is on the rise due to its contribution to a precise diagnosis, which is necessary for appropriate treatment and control of a plethora of genetic conditions. The fact of its broad fields of using from rare genetical diseases till common conditions brings attention to this issue in medical sector. An investigation that appeared in the Journal of Molecular Diagnostics revealed that the percentage of medical professionals who had integrated genetic diagnostic testing for hereditary cancers definitely had grown from 19.8% in 2014 to 38.4% in 2018.
Cytogenetic Testing and Chromosome Analysis
Biochemical Testing
Molecular Testing
DNA Sequencing
Others
Molecular testing holds the largest share in the industry
A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes cytogenetic testing and chromosome analysis, biochemical testing, and molecular testing (DNA sequencing, and others). According to the report, molecular testing accounted for the largest market share.
Molecular testing represents the largest section in the market. The methodology portion cover PCR, NGS, and other filtered DNA related analysis terms. It is very practical as it can be applied for many sections, from detecting genetic changes that give rise to diseases, to exploring cancer genetics for the reason of targeted treatments, and to unearthing genetic predispositions for different conditions. The unique capability of molecular testing associated with the precision it offers has established the field of genetic diagnostics, individualized medicine, and research as a key area in molecular science, giving it a leading position in this field. A 2021 study evaluated various COVID-19 molecular tests, revealing a high sensitivity rate of 95.9% for minimizing false negatives, and a specificity rate of 97.2% to reduce false positives. Besides, cytogenetic testing, including chromosome analysis means looking through section of chromosome in attempted to get information about chromosomal abnormalities of the patient. This part has a vital role in recognition the chromosome count, missing only one chromosome could cause genetic disorders such as Down syndrome, Klinefelter syndrome or Turner syndrome. It is widely use in pre-natal testing, cancer diagnosis and also for studying cells chromosome change, which are hardly beyond disease.
The biochemical testing, on the other hand, is directed towards the measurement of the exact amount of activity in most cases of specific enzymes in the body or the levels of proteins, hormones and other substances that comprise the body. This segment is a vital step in identifying metabolic disorders that result from enzyme deficiency by determining conditions like PKU or Tay- Sachs Disease, as possible causes.
Cancer Diagnosis
Genetic Disease Diagnosis
Cardiovascular Disease Diagnosis
Others
Genetic disease diagnosis represents the leading market segment
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. According to the report, genetic disease diagnosis represented the largest segment.
Genetic testing is currently utilized to diagnose a large number of diseases that are affected by both single-gene and multiple-gene factors. Genetic disease diagnosis is essential for the early detection of diseases and prompt intervention that finally aid in the condition's management. This growth is powered by its rear-rooted importance in the field of medicine which is represented in the accurate diagnoses of the genetic diseases not only for treatment but also for family planning. Between 2012 and 2022, the US led in the expansion of genetic tests, primarily for clinical diagnosis, highlighting the need for mandatory reporting and international collaboration for a comprehensive understanding of global genetic testing.
Using genetic analysis for cancer diagnosis implies finding out genetic mutations or alterations which cause cancer to develop. This portion is very vital for early tumor detection, diagnosis and controlling different categories of cancer.
Moreover, the genetic diagnosis of cardiovascular diseases involves locating these genetic variants to establish an increased risk for such heart-related defects as congenital heart defects, various cardiomyopathies, and arrhythmias.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest genetic testing market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America is the largest segment in the world market, driven by the world class healthcare infrastructure, the high amount of money that is spent on the healthcare sector and the presence of top companies and research institutions. The region is propelled by strong private investment, in the field of personalized medicine, large investments by governments in gene research, and favorable policy decisions from the national government. Besides, genetic disorders as well as chronic diseases, with a growing number of patients and informed population ready to access testing services, boost propel this company's leading position in the market.
The European region remains of crucial importance in terms of the market structure which is based on well-developed healthcare systems and governmental financial support of genetic research. The locale's market growth is propelled by the growing awareness about genetic DNA, personalized medicine, and the availability of qualified personnel in the field of genetics.
The Asia Pacific region is experiencing a growing market come from the fact that it is a large population base, infrastructure on healthcare rising and increasing the expenditure on healthcare. The market also draws support from genetic disease awareness growth, personalized medicine demanded growth, and government initiatives in health care reform.
The Latin American market is developing steadily, it is stimulated by improvement of the healthcare infrastructure, by the growth of the wages, and by the increase in public health awareness. As region is faced with the increasing demand for testing services for diseases prevention, diagnosis, and treatment.
The middle east and Africa market holds a lot of promise of significant growth. Factors that include the rising number of healthcare expenditure, the growing prevalence of genetic diseases, as well as the heightened level of awareness of the significant effects of genetic testing across the industry are the major drivers of genetic testing in this part of the world.
Market's key players adopt different strategies to achieve fundamental objective of strengthening their market share. This include is investing heavily in research and development to innovation and evolution of genetic testing technologies, especially in the direction of next-generation sequencing (NGS) and CRISPR. They also engage in the establishment of partnerships and collaboration with other biotech companies, academic institutions, as well as healthcare providers to help them grow in their services portfolio and geographical reach. Besides this, manufacturers are making efforts to get the new devices approved by the regulator agencies to be in compliance with regulations and guarantee the patient safety. Additionally, direct-to-consumer services have been developed with the aim of leveraging consumers' growing demand for personalized healthcare and genetic wellness.
23andme Inc.
Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)
Bio-RAD Laboratories Inc.
Cepheid (Danaher Corporation)
Eurofins Scientific
Illumina Inc.
Invitae Corporation
Luminex Corporation (DiaSorin)
Myriad Genetics Inc.
QIAGEN
Quest Diagnostics
Thermo Fisher Scientific
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)